Pancreatic cancer treatment depends heavily on whether the tumor can be surgically removed, and answering this question accurately requires a careful assessment of how the tumor relates to the major blood vessels running behind the pancreas. A detailed evaluation of resectability is essential for understanding the available treatment options and developing an appropriate surgical plan.
Fill out the form and our team will contact you shortly.
The single most important question in pancreatic cancer treatment is whether the tumor can be surgically removed at all, and answering it honestly, based on exactly how the tumor relates to the major blood vessels running behind the pancreas, matters more here than in almost any other cancer. Getting a clear, specific answer to that question is usually the first thing patients in Dubai need before anything else can be planned.
Dr. Ajeet Tiwari is an MCh surgical oncologist who reviews pancreatic cancer cases for patients in Dubai, assesses resectability based on imaging, and sets out a realistic treatment plan, whether that means surgery, chemotherapy first, or a combined approach.
This page explains how that clinical assessment is made and what surgical pathways—including the Whipple procedure and distal pancreatectomy—involve.
Diagnosis typically combines a multiphase pancreatic-protocol CT scan with contrast, high-resolution MRI, and a blood test for the CA 19-9 tumor marker (which supports monitoring rather than providing an isolated definitive diagnosis). Scans are evaluated specifically for vascular involvement, focusing on critical structures like the superior mesenteric artery, celiac axis, and portal vein to determine resectability.
Tumor relationship to surrounding retroperitoneal vasculature dictates immediate surgical feasibility and guides whether upfront surgery or downstaging therapy is required.
| Category | What It Means |
|---|---|
| Resectable | The tumor does not involve major blood vessels; surgery can generally proceed safely as the primary first step |
| Borderline resectable | The tumor touches or minimally involves nearby vessels; chemotherapy is typically administered first to improve chances of clear surgical margins (R0 resection) |
| Locally advanced (unresectable) | The tumor significantly encases major arterial or venous vessels; treatment prioritizes systemic chemotherapy and, in selected cases, radiotherapy |
| Metastatic | Cancer cells have spread beyond the regional pancreas; multidisciplinary management focuses on systemic therapy and symptom control |
The operative approach depends directly on the anatomical site of the tumor within the gland. Tumors located in the head or uncinate process necessitate a Whipple procedure, whereas lesions situated in the body or tail are managed with a distal pancreatectomy.
A Whipple procedure (pancreaticoduodenectomy) involves surgical resection of the pancreatic head, duodenum, gallbladder, and distal bile duct, followed by meticulous reconstruction of the pancreatic, biliary, and gastrointestinal tracts. As one of the most complex abdominal surgeries, typical hospital stay ranges between 10 to 14 days with close post-operative monitoring.
For tumors originating in the body or tail of the pancreas, a distal pancreatectomy removes the distal portion of the gland, typically combined with splenectomy to ensure comprehensive regional lymph node clearance. Recovery is generally shorter than a Whipple procedure as complex digestive reconstructions are not required.
For borderline resectable lesions—and increasingly in select resectable tumors—neoadjuvant chemotherapy delivers crucial clinical advantages: shrinking the tumor away from mesenteric vasculature, addressing micrometastatic disease early, and maximizing the probability of achieving negative resection margins.
Treatment cost depends on whether neoadjuvant chemotherapy protocols are required prior to surgery, the exact surgical procedure indicated (Whipple vs. distal pancreatectomy), vascular reconstruction needs, and total hospital stay. A written, itemized cost estimate is shared after imaging evaluation.
The second opinion pathway serves patients evaluating pancreatic surgery from Riyadh, Jeddah, and Kuwait. Pancreatic-protocol CT scans, MRIs, and CA 19-9 laboratory panels completed in local hospitals can be sent for assessment, followed by a dedicated video consultation.
Upload your contrast-enhanced CT/MRI scans, CA 19-9 lab results, and biopsy reports via our second opinion portal. You will receive an oncologist resectability analysis followed by a video discussion with Dr. Ajeet Tiwari detailing surgery and systemic sequencing.
If you have CT or MRI imaging and want a clear, specific answer on whether surgery is possible, send it through the online second opinion page before deciding anything.
Request Case ReviewFind answers to common questions about pancreatic cancer surgery, resectability criteria, the Whipple procedure, distal pancreatectomy, and international patient care.